Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation
Diabetes Mellitus, Type 2
A reduction in PK11195 uptake was observed in both enhancing and chronic lesions after the start of natalizumab. PK11195 PET can be used as tool to assess the longitudinal change in MS lesions.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency